Allogenetics

Allogenetics provides a unique solution to the problem of organ rejection following transplantation.

Health and bio

Allogenetics raised $3.8M in a Seed round announced September 9, 2026, according to biospace.com. Investors in that round: NBank Capital, Carma Fund, Life Science Valley Wachstumsfond.

Founders and team

• CF
  Constanca Figueiredo Founder

  source: crunchbase.com
• PL
  Phillipp Langrehr Founder

  source: crunchbase.com
• RB
  Rainer Blasczyk Founder

  source: crunchbase.com
• OE
  Oliver Ernst CEO and Managing Director

  source: crunchbase.com
• JR
  Jeroen Rovers Chief Medical Officer

  source: crunchbase.com

Raise history

1. September 9, 2026
   Seed · $3.8M
   NNBank Capital (lead), CCarma Fund, LLife Science Valley Wachstumsfond
   Source: biospace.com

Investors

• CCarma Fund
• LLife Science Valley Wachstumsfond
• NNBank Capital

Related bio health companies

• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/allogenetics.